Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Joseph M. Herman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9933-5227; OpenAlex author ID A5017770748, A5054516794, A5089299130. Sources: funder_awards.

Their work

Papers
179 (first author 15, last author 40)
Trials
0
Grants
1
Labs led
4
Collaborators
441
Papers, trials and grants by year

2008: 1 grant · 2009: none · 2010: none · 2011: 8 papers · 2012: 13 papers · 2013: 18 papers · 2014: 15 papers · 2015: 13 papers · 2016: 11 papers · 2017: 14 papers · 2018: 15 papers · 2019: 11 papers · 2020: 9 papers · 2021: 13 papers · 2022: 13 papers · 2023: 10 papers · 2024: 8 papers · 2025: 4 papers · 2026: 4 papers

Papers 50 of 179

  1. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  2. Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Do… Co-author DOI 10.1200/op-25-01431↗
  3. Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity. Co-author DOI 10.1016/j.ijrobp.2022.07.1120↗
  4. Nourishing Hope: Five Essential Nutrition Tips for Patients With Pancreatic Cancer. Last author DOI 10.6004/jadpro.2026.17.2.2↗
  5. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  6. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Last author DOI 10.1016/j.ijrobp.2024.10.039↗
  7. Adjuvant Radiation for Resected Pancreatic Cancer: Historical Review and Current State. Co-author DOI 10.1016/j.semradonc.2025.07.009↗
  8. Personalizing Patient Education for Pancreatic Cancer Patients Receiving Multidisciplinary Care with Integration of Novel Digital Tools. Co-author DOI 10.3390/healthcare13151929↗
  9. Comparison of neoadjuvant chemotherapy plus radiation vs. chemotherapy alone on complete pathologic response in pancreatic adenocarcinoma: an analysis of the n… Co-author DOI 10.1007/s44337-024-00145-0↗
  10. A Multi-Institutional Safety and Feasibility Study Exploring the Use of Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients wit… Co-author DOI 10.1016/j.prro.2023.11.011↗
  11. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
  12. Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting. Co-author DOI 10.1245/s10434-024-15352-3↗
  13. ASO Author Reflections: Identifying and Understanding How Vulnerable Populations Are Affected by Delays in Pancreatic Cancer Care. Co-author DOI 10.1245/s10434-024-15476-6↗
  14. Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A02150… Co-author DOI 10.1245/s10434-024-15670-6↗
  15. Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design. Co-author DOI 10.2217/fon-2022-1219↗
  16. Variation in outcomes and practice patterns among patients with localized pancreatic cancer: the impact of the pancreatic cancer multidisciplinary clinic. Co-author DOI 10.3389/fonc.2024.1427775↗
  17. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply. First author DOI 10.1001/jamaoncol.2022.6147↗
  18. Effectiveness of the nutrition referral system in a multidisciplinary pancreatic cancer clinic. Co-author DOI 10.1007/s00520-023-07795-3↗
  19. Proton Therapy for Unresectable and Medically Inoperable Locally Advanced Pancreatic Cancer: Results From a Multi-Institutional Prospective Registry. Co-author DOI 10.1016/j.adro.2023.101250↗
  20. The Current Role of Radiation in Pancreatic Cancer and Future Directions. First author DOI 10.1016/j.clcc.2023.01.002↗
  21. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  22. Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501). Co-author DOI 10.1097/sla.0000000000005958↗
  23. Development of a Neoadjuvant Treatment Pathway to Standardize Pancreatic Cancer Care and Improve Outcomes Across a Large Diverse Health System Co-author DOI 10.1101/2023.09.19.23295749↗
  24. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therap… Co-author DOI 10.1200/po.21.00489↗
  25. The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15041252↗
  26. Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers15225355↗
  27. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  28. Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.clon.2021.12.014↗
  29. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2022.04.044↗
  30. Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical … Co-author DOI 10.1016/j.prro.2022.01.005↗
  31. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Last author DOI 10.1016/j.prro.2022.02.009↗
  32. Advance care planning in patients undergoing surgery to resect pancreatic adenocarcinoma: Underlying tension between balancing hope and realism. Co-author DOI 10.1016/j.surg.2021.08.033↗
  33. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000005558↗
  34. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  35. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Last author DOI 10.1245/s10434-021-11202-8↗
  36. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resecta… Co-author DOI 10.21037/jgo-21-513↗
  37. Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection. Co-author DOI 10.21037/jgo-22-38↗
  38. Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Insti… Co-author DOI 10.3390/curroncol29010028↗
  39. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and s… Co-author DOI 10.3857/roj.2021.01060↗
  40. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2020.11.006↗
  41. Geometric Reproducibility of Fiducial Markers and Efficacy of a Patient-Specific Margin Design Using Deep Inspiration Breath Hold for Stereotactic Body Radiati… Co-author DOI 10.1016/j.adro.2021.100655↗
  42. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Co-author DOI 10.1016/j.adro.2021.100763↗
  43. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2020.11.017↗
  44. Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma: A Singl… First author DOI 10.1097/mpa.0000000000001724↗
  45. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  46. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and o… Co-author DOI 10.1101/2021.12.16.21267326↗
  47. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  48. Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy? Co-author DOI 10.1186/s13014-021-01782-w↗
  49. Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. Co-author DOI 10.1186/s13014-021-01969-1↗
  50. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗

Grants 1

  1. Evaluation of Focused Radiation to Potentiate a Pancreatic GM-CSF Vaccine AWARD pancan:2008-joseph-michael-herman-md-evaluation-of-focused-radiation-to-poten

Closest collaborators

The 25 strongest of 441 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amol Kumar Narang · 44 shared papers, 2012–2026 · strength 5.50
  2. Lei Zheng · 39 shared papers, 2012–2026 · strength 3.42
  3. Jin Peng He · 29 shared papers, 2013–2026 · strength 3.30
  4. Colin Hill · 18 shared papers, 2021–2026 · strength 3.08
  5. Daniel A. Laheru · 46 shared papers, 2011–2026 · strength 3.01
  6. Christopher Lee Wolfgang · 52 shared papers, 2011–2022 · strength 2.41
  7. Jeffrey John Meyer · 15 shared papers, 2020–2026 · strength 2.37
  8. Matthew H. G. Katz · 20 shared papers, 2013–2026 · strength 2.31
  9. Matthew John Weiss · 24 shared papers, 2015–2024 · strength 2.26
  10. Amy Hacker‐Prietz · 26 shared papers, 2012–2025 · strength 2.09
  11. Shuchi Sehgal · 13 shared papers, 2021–2026 · strength 2.05
  12. Eugene Jon Koay · 20 shared papers, 2017–2024 · strength 1.98
  13. Abhinav V. Reddy · 12 shared papers, 2021–2026 · strength 1.96
  14. Lauren M. Rosati · 23 shared papers, 2014–2025 · strength 1.77
  15. Dung Thi Le · 21 shared papers, 2011–2026 · strength 1.65
  16. Timothy Michael Pawlik · 33 shared papers, 2011–2025 · strength 1.52
  17. Ralph H. Hruban · 34 shared papers, 2011–2022 · strength 1.52
  18. Albert C. Koong · 21 shared papers, 2012–2023 · strength 1.42
  19. Cullen M. Taniguchi · 13 shared papers, 2018–2023 · strength 1.26
  20. Eileen Mary O'Reilly · 7 shared papers, 2015–2026 · strength 1.15
  21. Robert A. Wolff · 15 shared papers, 2012–2023 · strength 1.12
  22. Lyudmyla Demyan · 6 shared papers, 2022–2024 · strength 1.00
  23. Ana De Jesus‐Acosta · 13 shared papers, 2013–2022 · strength 0.99
  24. Elizabeth M. Jaffee · 12 shared papers, 2011–2026 · strength 0.95
  25. Karyn A. Goodman · 9 shared papers, 2013–2025 · strength 0.95

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.